Literature DB >> 16382342

Role of phosphate-activated glutaminase in the pathogenesis of hepatic encephalopathy.

Manuel Romero-Gómez1.   

Abstract

Disturbed body nitrogen homeostasis due to impaired hepatic urea synthesis leads to an alteration in inter-organ ammonia trafficking, resulting in hyperammonemia. Glutamine (Gln) synthase is the alternative pathway for ammonia detoxification. Gln taken up by several organs is split by the intramitochondrial phosphate-activated enzyme glutaminase (PAG) into glutamate (Glu) and ammonia. In cirrhotic patients with portosystemic intrahepatic shunt, the main source of systemic hyperammonemia is the small intestine, and ammonia derives mainly from Gln deamidation. Recently, PAG has been found increased in cirrhotics showing minimal hepatic encephalopathy and, therefore, could be implicated in the production of systemic hyperammonemia in these patients. Intestinal PAG activity correlates with psychometric test and magnetic resonance spectroscopy findings. Moreover, nitric oxide and tumor necrosis factor seem to be the major factors regulating intestinal ammonia production in cirrhotics. In the brain, PAG localized into the astrocytes is responsible for ammonia and free-radical production. The blockade of PAG, using 6-oxo-5-norleucine, avoids the toxic effects of Gln accumulation in the brain. These data support an important role for intestinal and brain glutaminase in the pathogenesis of hepatic encephalopathy and could be a new target for future therapies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16382342     DOI: 10.1007/s11011-005-7913-5

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  26 in total

Review 1.  [New concepts in the physiopathology of hepatic encephalopathy and therapeutic prospects].

Authors:  M Romero Gómez; J D Bautista; L Grande; R M Ramos Guerrero; D Sánchez Muñoz
Journal:  Gastroenterol Hepatol       Date:  2004-02       Impact factor: 2.102

2.  The importance of the small intestine in gut ammonium production in the fasting dog.

Authors:  F L Weber; G L Veach
Journal:  Gastroenterology       Date:  1979-08       Impact factor: 22.682

3.  Eck's fistula encephalopathy in germfree dogs.

Authors:  F C Nance; D G Kline
Journal:  Ann Surg       Date:  1971-11       Impact factor: 12.969

Review 4.  Chronic portal systemic encephalopathy: update 1987.

Authors:  S Sherlock
Journal:  Gut       Date:  1987-08       Impact factor: 23.059

5.  Hormonal stimulation of mitochondrial glutaminase. Effects of vasopressin, angiotensin II, adrenaline and glucagon.

Authors:  S Corvera; J A García-Sáinz
Journal:  Biochem J       Date:  1983-03-15       Impact factor: 3.857

6.  Induced hyperammonemia alters neuropsychology, brain MR spectroscopy and magnetization transfer in cirrhosis.

Authors:  Sherzad Balata; Steven W M Olde Damink; Karen Ferguson; Ian Marshall; Peter C Hayes; Nicolaas E p Deutz; Roger Williams; Joanna Wardlaw; Rajiv Jalan
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

7.  Analysis of hepatic encephalopathy after distal splenorenal shunt--PTP image and pancreatic hormone kinetics.

Authors:  N Hashimoto; H Ashida; Y Kotoura; A Nishioka; M Nishiwaki; J Utsunomiya
Journal:  Hepatogastroenterology       Date:  1993-08

8.  Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid.

Authors:  Rajiv Jalan; Dharmesh Kapoor
Journal:  Clin Sci (Lond)       Date:  2004-05       Impact factor: 6.124

Review 9.  Ammonia neurotoxicity and the mitochondrial permeability transition.

Authors:  M D Norenberg; K V Rama Rao; A R Jayakumar
Journal:  J Bioenerg Biomembr       Date:  2004-08       Impact factor: 2.945

10.  Neomycin reduces the intestinal production of ammonia from glutamine.

Authors:  R A Hawkins; J Jessy; A M Mans; A Chedid; M R DeJoseph
Journal:  Adv Exp Med Biol       Date:  1994       Impact factor: 2.622

View more
  7 in total

1.  Modification in CSF specific gravity in acutely decompensated cirrhosis and acute on chronic liver failure independent of encephalopathy, evidences for an early blood-CSF barrier dysfunction in cirrhosis.

Authors:  Nicolas Weiss; Matteo Rosselli; Sarah Mouri; Damien Galanaud; Louis Puybasset; Banwari Agarwal; Dominique Thabut; Rajiv Jalan
Journal:  Metab Brain Dis       Date:  2016-10-11       Impact factor: 3.584

Review 2.  Gut microbiota in liver disease: too much is harmful, nothing at all is not helpful either.

Authors:  Phillipp Hartmann; Huikuan Chu; Yi Duan; Bernd Schnabl
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-02-15       Impact factor: 4.052

3.  Gut microbiota drive the development of neuroinflammatory response in cirrhosis in mice.

Authors:  Dae Joong Kang; Naga S Betrapally; Siddhartha A Ghosh; R Balfour Sartor; Phillip B Hylemon; Patrick M Gillevet; Arun J Sanyal; Douglas M Heuman; Daniel Carl; Huiping Zhou; Runping Liu; Xiang Wang; Jing Yang; Chunhua Jiao; Jeremy Herzog; H Robert Lippman; Masoumeh Sikaroodi; Robert R Brown; Jasmohan S Bajaj
Journal:  Hepatology       Date:  2016-07-29       Impact factor: 17.425

Review 4.  Gut ammonia production and its modulation.

Authors:  Manuel Romero-Gómez; María Jover; J Jorge Galán; A Ruiz
Journal:  Metab Brain Dis       Date:  2008-12-10       Impact factor: 3.584

Review 5.  Role of diabetes mellitus on hepatic encephalopathy.

Authors:  Javier Ampuero; Isidora Ranchal; María del Mar Díaz-Herrero; José Antonio del Campo; Juan D Bautista; Manuel Romero-Gómez
Journal:  Metab Brain Dis       Date:  2012-11-24       Impact factor: 3.584

6.  Metformin inhibits glutaminase activity and protects against hepatic encephalopathy.

Authors:  Javier Ampuero; Isidora Ranchal; David Nuñez; María del Mar Díaz-Herrero; Marta Maraver; José Antonio del Campo; Ángela Rojas; Inés Camacho; Blanca Figueruela; Juan D Bautista; Manuel Romero-Gómez
Journal:  PLoS One       Date:  2012-11-15       Impact factor: 3.240

7.  Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition.

Authors:  Dae J Kang; Genta Kakiyama; Naga S Betrapally; Jeremy Herzog; Hiroshi Nittono; Phillip B Hylemon; Huiping Zhou; Ian Carroll; Jing Yang; Patrick M Gillevet; Chunhua Jiao; Hajime Takei; William M Pandak; Takashi Iida; Douglas M Heuman; Sili Fan; Oliver Fiehn; Takao Kurosawa; Masoumeh Sikaroodi; R B Sartor; Jasmohan S Bajaj
Journal:  Clin Transl Gastroenterol       Date:  2016-08-25       Impact factor: 4.488

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.